[{"NetIncomeLoss_1_Q2_USD":-52492000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":257973329.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":257548623.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q2_USD":4865000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":6536000.0,"BusinessCombinationContingentConsiderationLiability_0_Q2_USD":24327000.0,"InterestPaidNet_2_Q2_USD":10709000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":163258000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_2_Q2_USD":-554000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_1_Q2_USD":-2090000.0,"LiabilitiesFairValueDisclosure_0_Q2_USD":27639000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":2080000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":-2116000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":4000.0,"AssetsCurrent_0_Q2_USD":383884000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":74872000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":34657000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":145017000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":4571000.0,"CommonStockSharesIssued_0_Q2_shares":258223842.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":210139000.0,"InterestExpenseDebtExcludingAmortization_1_Q2_USD":3410000.0,"InterestExpenseDebtExcludingAmortization_2_Q2_USD":6995000.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":2203000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":8408000.0,"InventoryValuationReserves_0_Q2_USD":200000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":4656000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":10733000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":28915000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":6676000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":13228000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_2_Q2_USD":21004000.0,"MarketableSecuritiesCurrent_0_Q2_USD":145017000.0,"DeferredCreditsAndOtherLiabilitiesNoncurrent_0_Q2_USD":8906000.0,"Liabilities_0_Q2_USD":340498000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1_Q2_USD":-554000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-23916000.0,"WarrantsAndRightsOutstanding_0_Q2_USD":12387000.0,"CommonStockValue_0_Q2_USD":2614000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":3703000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":4064000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_2_Q2_USD":-8097000.0,"AccountsReceivableNetCurrent_0_Q2_USD":43040000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-2990000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q2_USD":0.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":0.0,"AssetsFairValueDisclosure_0_Q2_USD":148251000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":38000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":457000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":5326000.0,"Assets_0_Q2_USD":701451000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":3803000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2_Q2_USD":-1646000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":2250849000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":43666000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":164573000.0,"OtherAssetsNoncurrent_0_Q2_USD":25876000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-54151000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-139112000.0,"DepreciationDepletionAndAmortization_1_Q2_USD":2039000.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q2_USD":85478000.0,"DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_0_Q2_USD":3312000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_Q2_USD":1646000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":2599000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":69611000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":158731000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1_Q2_USD":-715000.0,"IncreaseDecreaseInInventories_2_Q2_USD":-1351000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":248000.0,"ShareBasedCompensation_2_Q2_USD":21004000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":0.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":21194000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":2328000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-1659000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":490000.0,"Goodwill_0_Q2_USD":197797000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-137376000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-48789000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2_Q2_USD":66000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1_Q2_USD":122000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-141460000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":1872000.0,"ProceedsFromWarrantExercises_2_Q2_USD":0.0,"LiabilitiesCurrent_0_Q2_USD":108300000.0,"AccountsPayableCurrent_0_Q2_USD":14306000.0,"InterestExpense_2_Q2_USD":7364000.0,"InterestExpense_1_Q2_USD":3635000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":167262000.0,"NetIncomeLoss_2_Q2_USD":-141440000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":46945000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q2_USD":20027000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":502000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":5051000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q2_USD":17700000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":45005000.0,"DebtSecuritiesRealizedGainLoss_2_Q2_USD":0.0,"GrossProfit_1_Q2_USD":55677000.0,"GrossProfit_2_Q2_USD":109650000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":23000000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":164573000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":10734000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":18275000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q2_USD":288000.0,"CommonStockSharesOutstanding_0_Q2_shares":258223842.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":10388000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":20921000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":8408000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":21004000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":701451000.0,"InvestmentIncomeInterest_1_Q2_USD":865000.0,"InvestmentIncomeInterest_2_Q2_USD":2380000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q2_USD":24327000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":474000.0,"InventoryNet_0_Q2_USD":12979000.0,"OperatingIncomeLoss_1_Q2_USD":-51345000.0,"OperatingIncomeLoss_2_Q2_USD":-129402000.0,"CommonStockSharesAuthorized_0_Q2_shares":500000000.0,"SecuredLongTermDebt_0_Q2_USD":147834000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-1375000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"AllowanceForDoubtfulAccountsReceivable_0_Q2_USD":100000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":23949000.0,"AmortizationOfDebtDiscountPremium_1_Q2_USD":268000.0,"OperatingExpenses_2_Q2_USD":239052000.0,"PaymentsForTenantImprovements_2_Q2_USD":455000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1910050000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":532000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q2_USD":62353000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":122878000.0,"RestrictedCashAndCashEquivalents_0_Q2_USD":2689000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":8516000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":144531000.0,"StockholdersEquity_0_Q2_USD":360953000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":4511000.0,"ProfitLoss_2_Q2_USD":-141440000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.2,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.55,"OperatingExpenses_1_Q2_USD":107022000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":1876000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-3476000.0,"Ticker":"FOLD","CIK":"1178879","name":"AMICUS THERAPEUTICS, INC.","OfficialName":"Amicus Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"2296240629.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200810"}]